Sun Pharmaceutical has seen a notable 36% drop in net profit, juxtaposed with an 11.8% rise in consolidated revenue. The uplift in revenue can be attributed largely to strong sales growth in India and emerging markets, particularly in domestic formulations. Conversely, US formulation sales faced a significant downturn. The company also marked progress in its integration planning for the acquisition of Organon, following the successful completion of regulatory approvals.
ET Wealth Expo: Why market veteran S Naren thinks investors are getting gold, silver and asset allocation all wrong
ICICI Prudential MF’s S Naren warns investors against chasing assets after spectacular rallies, highlighting how silver’s 216% surge drew record ETF inflows before a 27%
October 31, 2026